Editing GSK plc (section)

==History==
===Glaxo Wellcome===
[[File:Glaxo Factory, Bunnythorpe, New Zealand 03.JPG|thumb|The Glaxo factory built in 1918, in [[Bunnythorpe|Bunnythorpe, New Zealand]], with the Glaxo Laboratories sign still visible]]

====Glaxo====
Joseph Nathan and Co. was founded in 1873, as a general trading company in [[Wellington]], New Zealand, by a Londoner, [[Joseph Nathan|Joseph Edward Nathan]].<ref>R. P. T. Davenport-Hines, Judy Slinn, ''Glaxo: A History to 1962'', Cambridge University Press, 1992, pp.&nbsp;7–13.</ref> In 1904, it began producing a dried-milk baby food from excess milk produced on dairy farms near [[Bunnythorpe]]. The resulting product was first known as Defiance, then as Glaxo (from ''lacto''), and sold with the slogan "Glaxo builds bonnie babies."<ref>David Newton, ''Trademarked: A History of Well-Known Brands, from Airtex to Wright's Coal Tar'', The History Press, 2012, p.&nbsp;435.</ref><ref name="Ravenscraft2000">{{Cite web |last1=Ravenscraft |first1=David J. |last2=Long |first2=William F. |date=January 2000 |title=Paths to Creating Value in Pharmaceutical Mergers |url=https://www.nber.org/system/files/chapters/c8653/c8653.pdf |url-status=live |archive-url=https://web.archive.org/web/20230107075228/https://www.nber.org/system/files/chapters/c8653/c8653.pdf |archive-date=7 January 2023 |website=National Bureau of Economic Research}}</ref>{{rp|306}}<ref name="history"/> The Glaxo Laboratories sign is still visible on what is now a car repair shop on the main street of Bunnythorpe. The company's first pharmaceutical product, released in 1924, was vitamin D.<ref name=Ravenscraft2000/>{{rp|306}}
[[File:Glaxo feeder bottle with packaging.jpg|thumb|right| Feeder bottle with valve and teat, Glaxo Laboratories, Greenford, Middlesex]]

Glaxo Laboratories was incorporated as a distinct subsidiary company in London in 1935.<ref>New "Glaxo" Company. ''The Times'', Tuesday, 15 October 1935; pg. 22; Issue 47195</ref> Joseph Nathan's shareholders reorganised the group's structure in 1947, making Glaxo the parent<ref>J. Nathan And "Glaxo" Reorganization. ''The Times'', Wednesday, 8 January 1947; pg. 8; Issue 50653</ref> and obtained a listing on the [[London Stock Exchange]].<ref>Joseph Nathan & Co. ''The Times'', Thursday, 20 February 1947; pg. 8; Issue 50690</ref> Glaxo acquired [[Allen & Hanburys]] in 1958. The Scottish pharmacologist [[David Jack (scientist)|David Jack]] was hired as a researcher for Allen & Hanburys a few years after Glaxo took it over; he went on to lead the company's [[research and development]] (R&D) until 1987.<ref name=Ravenscraft2000/>{{rp|306}} After Glaxo bought Meyer Laboratories in 1978, it began to play an important role in the US market. In 1983, the American arm, Glaxo Inc., moved to [[Research Triangle Park]] (US headquarters/research) and Zebulon (US manufacturing) in [[North Carolina]].<ref name="history"/>

====Burroughs Wellcome====
Burroughs Wellcome & Company was founded in 1880, in London by the American pharmacists [[Henry Wellcome]] and [[Silas Mainville Burroughs (pharmacist)|Silas Burroughs]].<ref name=":1">{{Cite book |last=Kumar |first=B. Rajesh |title=Mega Mergers and Acquisitions: Case Studies from Key Industries |publisher=Springer |year=2012 |isbn=978-1-137-00590-8 |location=Cham |pages=14 |language=en}}</ref> The Wellcome Tropical Research Laboratories opened in 1902. In the 1920s, Burroughs Wellcome established research and manufacturing facilities in [[Tuckahoe (village), New York|Tuckahoe, New York]],<ref name="TriCent">{{Cite web |title=Eastchester: History of the Town |url=http://eastchester350.org/350/wp-content/uploads/2014/04/History-of-the-town-1964.pdf |url-status=dead |archive-url=https://web.archive.org/web/20160401183707/http://eastchester350.org/350/wp-content/uploads/2014/04/History-of-the-town-1964.pdf |archive-date=1 April 2016}}</ref>{{rp|18}}<ref>[http://news.hrvh.org/veridian/cgi-bin/senylrc?a=d&d=theeastchester19241119.1.2 "Addition to Factory"] {{Webarchive|url=https://web.archive.org/web/20201201140948/https://news.hrvh.org/veridian/cgi-bin/senylrc?a=d&d=theeastchester19241119.1.2 |date=1 December 2020 }}, ''The Eastchester Citizen-Bulletin'', 19 November 1924</ref><ref>Peter Pennoyer, Anne Walker, ''The Architecture of Delano & Aldrich'', W. W. Norton & Company, 2003, p.&nbsp;[https://books.google.com/books?id=PfsvwzwaQqUC&pg=PA188 188].</ref> which served as the US headquarters until the company moved to [[Research Triangle Park]] in North Carolina in 1971.<ref>[http://recentpast.org/iconic-burroughs-wellcome-headquarters-open-for-rare-public-tour/ "Iconic Burroughs Wellcome Headquarters Open for Rare Public Tour"] {{Webarchive |url=https://web.archive.org/web/20180828173230/http://recentpast.org/iconic-burroughs-wellcome-headquarters-open-for-rare-public-tour/ |date=28 August 2018 }}, Triangle Modernist Houses, press release, 8 October 2012.</ref><ref name="Cummings">{{cite web |last1=Cummings |first1=Alex Sayf |date=13 June 2016 |title=Into the Spaceship: A Visit to the Old Burroughs Wellcome Building |url=https://tropicsofmeta.com/2016/06/13/into-the-spaceship-a-visit-to-the-old-burroughs-wellcome-building/ |url-status=live |archive-url=https://web.archive.org/web/20230411175810/https://tropicsofmeta.com/2016/06/13/into-the-spaceship-a-visit-to-the-old-burroughs-wellcome-building/ |archive-date=11 April 2023 |access-date=25 November 2019 |website=Tropics of Meta historiography for the masses}}</ref> The [[Nobel Prize]] winning scientists [[Gertrude B. Elion]] and [[George H. Hitchings]] worked there and invented drugs still used many years later, such as [[mercaptopurine]].<ref>{{cite news |last=Bouton |first=Katherine |date=29 January 1989 |title=The Nobel Pair |website=[[The New York Times]] |url=https://www.nytimes.com/1989/01/29/magazine/the-nobel-pair.html |url-status=live |access-date=12 March 2020 |archive-url=https://web.archive.org/web/20221017153346/https://www.nytimes.com/1989/01/29/magazine/the-nobel-pair.html |archive-date=17 October 2022}}</ref> In 1959, the [[Wellcome Foundation]] bought [[William Cooper (chemical manufacturer)|Cooper, McDougall & Robertson Inc]] to become more active in animal health.<ref name="history">{{cite web |url=http://www.gsk.com/about/history-noflash.htm |title=GSK History |publisher=GlaxoSmithKline |access-date=18 April 2011 |url-status=dead |archive-url=https://web.archive.org/web/20110608203248/http://www.gsk.com/about/history-noflash.htm |archive-date=8 June 2011}}</ref>

When Burroughs Wellcome decided to move its headquarters, the company selected [[Paul Rudolph (architect)|Paul Rudolph]] to design its new building.<ref>{{Cite book |last1=Kaji-O'Grady |first1=Sandra |title=LabOratory: Speaking of Science and Its Architecture |last2=Smith |first2=Chris L. |publisher=MIT Press |year=2019 |isbn=978-0-262-35636-7 |location=Cambridge, MA |pages=4–5 |language=en}}</ref> The [[Elion-Hitchings Building]] "was celebrated worldwide when it was built," according to Paul Rudolph Heritage Foundation president Kelvin Dickinson. Alex Sayf Cummings of [[Georgia State University]] wrote in 2016, that the "iconic building helped define the image of RTP," saying, "Love it or hate it, Rudolph's design remains an impressively audacious creative gesture and an important part of the history of both architecture and [[Research Triangle Park]]."<ref name="Elion-Hitchings"/> [[United Therapeutics]], which bought the building in 2012, announced plans in 2020, to tear it down.<ref name="Elion-Hitchings">{{cite news |last=Stradling |first=Richard |date=21 September 2020 |title=United Therapeutics to demolish an RTP landmark building |work=[[News & Observer]] |url=https://www.newsobserver.com/news/local/article245830330.html |url-status=live |archive-url=https://web.archive.org/web/20210106220235/https://www.newsobserver.com/news/local/article245830330.html |archive-date=6 January 2021}}</ref>

====Merger====
Glaxo and Wellcome merged in 1995, to form Glaxo Wellcome plc.<ref>{{Cite web |last=Lesney |first=Mark S. |date=January 2004 |title=The ghosts of pharma past |url=https://pubsapp.acs.org/subscribe/journals/mdd/v07/i01/pdf/104timeline.pdf |url-status=live |archive-url=https://web.archive.org/web/20230107075235/https://pubsapp.acs.org/subscribe/journals/mdd/v07/i01/pdf/104timeline.pdf |archive-date=7 January 2023}}</ref><ref name=Ravenscraft2000/> The merger was then considered the biggest in the UK corporate history.<ref name=":1" /> Glaxo Wellcome restructured its R&D operation that year, cutting 10,000 jobs worldwide, closing its R&D facility in Beckenham, Kent, and opening a Medicines Research Centre in [[Stevenage]], [[Hertfordshire]].<ref>{{cite news |last=Grimond |first=Magnus |date=15 June 1995 |title=10,000 face Glaxo's axe at Wellcome |newspaper=The Independent |url=https://www.independent.co.uk/news/business/10000-face-glaxos-axe-at-wellcome-1586547.html |url-status=live |archive-url=https://web.archive.org/web/20220706142050/https://www.independent.co.uk/news/business/10-000-face-glaxo-s-axe-at-wellcome-1586547.html |archive-date=6 July 2022}}</ref><ref>
{{cite news |url=https://www.independent.co.uk/news/business/glaxo-warns-of-redundancies-1587568.html |archive-url=https://web.archive.org/web/20140226160641/http://www.independent.co.uk/news/business/glaxo-warns-of-redundancies-1587568.html |url-status=dead |archive-date=26 February 2014 |last=Grimond |first=Magnus |title=Glaxo warns of redundancies |newspaper=The Independent |date=21 June 1995}}</ref><ref>{{cite news |last=Grimond |first=Magnus |date=7 September 1995 |title=Glaxo Wellcome plans to axe 7,500 jobs |newspaper=The Independent |url=https://www.independent.co.uk/news/business/glaxo-wellcome-plans-to-axe-7500-jobs-1600042.html |url-status=live |archive-url=https://web.archive.org/web/20221124164542/https://www.independent.co.uk/news/business/glaxo-wellcome-plans-to-axe-7-500-jobs-1600042.html |archive-date=24 November 2022}}</ref> Also that year, Glaxo Wellcome acquired the [[California]]-based Affymax, a leader in the field of [[combinatorial chemistry]].<ref>{{cite news |date=27 January 1995 |title=Glaxo to Acquire Affymax |website=[[The New York Times]] |url=https://www.nytimes.com/1995/01/27/business/glaxo-to-acquire-affymax.html |url-status=live |access-date=12 March 2020 |archive-url=https://web.archive.org/web/20230404164133/https://www.nytimes.com/1995/01/27/business/glaxo-to-acquire-affymax.html |archive-date=4 April 2023}}</ref>

By 1999, Glaxo Wellcome had become the world's third-largest pharmaceutical company by revenues (behind [[Novartis]] and Merck), with a global market share of around 4 per cent.<ref>{{cite news |date=30 March 1999 |title=Outlook: Glaxo Wellcome |newspaper=The Independent |url=https://www.independent.co.uk/news/business/outlook-glaxo-wellcome-1084036.html |url-status=live |archive-url=https://web.archive.org/web/20230316123746/https://www.independent.co.uk/news/business/outlook-glaxo-wellcome-1084036.html |archive-date=16 March 2023}}</ref> Its products included [[Imigran]] (for the treatment of migraine), [[salbutamol]] (Ventolin) (for the treatment of asthma), [[Zovirax]] (for the treatment of coldsores), and [[Retrovir]] and [[Epivir]] (for the treatment of AIDS). In 1999, the company was the world's largest manufacturer of drugs for the treatment of asthma and HIV/AIDS.<ref name="indep1899">{{cite news |date=1 August 1999 |title=Company of the week: Glaxo Wellcome |newspaper=The Independent |url=https://www.independent.co.uk/news/business/company-of-the-week-glaxo-wellcome-1109929.html |url-status=live |archive-url=https://web.archive.org/web/20221124161534/https://www.independent.co.uk/news/business/company-of-the-week-glaxo-wellcome-1109929.html |archive-date=24 November 2022}}</ref> It employed 59,000 people, including 13,400 in the UK, had 76 operating companies and 50 manufacturing facilities worldwide, and seven of its products were among the world's top 50 best-selling pharmaceuticals. The company had R&D facilities in Hertfordshire, [[Kent]], London and [[Verona]] (Italy), and manufacturing plants in Scotland and the north of England. It had R&D centres in the US and Japan, and production facilities in the US, Europe and the Far East.<ref name="bbc17100">{{cite news |date=17 January 2000 |title=Profile: Glaxo Wellcome |work=BBC News |url=http://news.bbc.co.uk/1/hi/business/606752.stm |url-status=live |archive-url=https://web.archive.org/web/20230412181754/http://news.bbc.co.uk/2/hi/business/606752.stm |archive-date=12 April 2023}}</ref>

===SmithKline Beecham===
====Beecham====
{{Main|Beecham Group}}
[[File:BeechamsBuilding.jpg|thumb|Beecham's Clock Tower, constructed 1877, part of the [[Beecham (pharmaceutical company)|Beecham]]'s factory, [[St Helens, Merseyside|St Helens]]]]
In 1848, [[Thomas Beecham (chemist)|Thomas Beecham]] launched his [[Beecham's Pills]] laxative in England, giving birth to the [[Beecham Group]]. In 1859, Beecham opened its first factory in [[St Helens, Merseyside|St Helens]], [[Lancashire]]. By the 1960s, Beecham was extensively involved in pharmaceuticals and consumer products such as [[Macleans (toothpaste)|Macleans toothpaste]], Lucozade and synthetic penicillin research.<ref name="history"/><ref>{{cite book |last1=Corely |first1=T.A.B. |title=Beechams, 1848-2000: from Pills to Pharmaceuticals |date=2011 |publisher=Crucible Books |isbn=978-1905472147}}</ref>

====SmithKline====
{{Main|Smith, Kline & French}}
[[John K. Smith]] opened his first pharmacy in Philadelphia in 1830. In 1865, [[Mahlon Kline]] joined the business, which 10 years later became Smith, Kline & Co. In 1891, it merged with French, Richard and Company, and in 1929, changed its name to [[Smith, Kline & French|Smith Kline & French Laboratories]] as it focused more on research. Years later it bought Norden Laboratories, a business doing research into animal health, and [[Recherche et Industrie Thérapeutiques]] in Belgium in 1963, to focus on vaccines. The company began to expand globally, buying seven laboratories in Canada and the United States in 1969. In 1982, it bought [[Allergan]], a manufacturer of eye and skincare products.<ref name="history"/>

Smith Kline & French merged with Beckman Inc. in 1982, and changed its name to ''SmithKline Beckman''.<ref>{{Cite news |last=Kleinfield |first=N. R. |date=29 May 1984 |title=Smithkline: One-Drug Image |work=[[The New York Times]] |url=https://www.nytimes.com/1984/05/29/business/smithkline-one-drug-image.html |url-status=live |access-date=30 September 2019 |archive-url=https://web.archive.org/web/20230405091137/https://www.nytimes.com/1984/05/29/business/smithkline-one-drug-image.html |archive-date=5 April 2023 |issn=0362-4331}}</ref> In 1988, it bought International Clinical Laboratories.<ref>{{Cite web |date=13 April 1988 |title=SmithKline Beckman Corp. and International Clinical Laboratories Inc. announced... |url=https://www.upi.com/Archives/1988/04/13/SmithKline-Beckman-Corp-and-International-Clinical-Laboratories-Inc-announced/3060576907200/ |url-status=live |archive-url=https://web.archive.org/web/20190930175210/https://www.upi.com/Archives/1988/04/13/SmithKline-Beckman-Corp-and-International-Clinical-Laboratories-Inc-announced/3060576907200/ |archive-date=30 September 2019 |access-date=30 September 2019 |website=UPI}}</ref>

====Merger====
In 1989, SmithKline Beckman merged with Beecham Group to form ''SmithKline Beecham P.L.C.''.<ref>{{Cite news |last=Lohr |first=Steve |date=13 April 1989 |title=SmithKline, Beecham to Merge |work=[[The New York Times]] |url=https://www.nytimes.com/1989/04/13/business/smithkline-beecham-to-merge.html |url-status=live |access-date=30 September 2019 |archive-url=https://web.archive.org/web/20230522171509/https://www.nytimes.com/1989/04/13/business/smithkline-beecham-to-merge.html |archive-date=22 May 2023 |issn=0362-4331}}</ref> The headquarters moved from the United States to England. To expand R&D in the United States, the company bought a new research center in 1995; another opened in 1997, in England at [[New Frontiers Science Park]], [[Harlow]].<ref name="history"/>

===2000: Glaxo Wellcome and SmithKline Beecham merger===
Glaxo Wellcome and SmithKline Beecham announced their intention to merge in January 2000. The merger was completed on 27 December that year, forming GlaxoSmithKline (GSK).<ref>{{cite news |date=20 January 2000 |title=The new alchemy – The drug industry's flurry of mergers is based on a big gamble |newspaper=The Economist |url=http://www.economist.com/node/275655 |url-status=live |archive-url=https://web.archive.org/web/20230725231652/https://www.economist.com/business/2000/01/20/the-new-alchemy |archive-date=25 July 2023}}</ref><ref>{{cite journal |title=Partners resolve their differences and unite at the second attempt |journal=Nature |date=May 2000 |volume=405 |issue=6783 |doi=10.1038/35012210 |pmid=10821289 |page=258 |vauthors=Gershon D |s2cid=23140509 |doi-access=free}}</ref> The company's global headquarters were at GSK House, [[Brentford]], London, officially opened in 2002, by then-Prime Minister [[Tony Blair]]. The building was erected at a cost of £300{{nbsp}}million and {{as of|2002|lc=yes}} was home to 3,000 administrative staff.<ref name=tele15702>{{cite news |url=https://www.telegraph.co.uk/finance/2767982/Hall-that-glitters-isnt-shareholder-gold.html |archive-url=https://ghostarchive.org/archive/20220111/https://www.telegraph.co.uk/finance/2767982/Hall-that-glitters-isnt-shareholder-gold.html |archive-date=11 January 2022 |url-access=subscription |url-status=live |title=Hall that glitters isn't shareholder gold |work=The Daily Telegraph |date=15 July 2002}}{{cbignore}}</ref>

===2001–2010===
[[File:Andrew Witty in 2015.jpg|thumb|alt=photograph|[[Andrew Witty]], GSK's CEO from May 2008, to April 2017]]

GSK completed the acquisition of New Jersey–based [[Block Drug]] in 2001, for {{US$|1.24 billion}}.<ref>{{cite web |title=GlaxoSmithKline Completes the Purchase of Block Drug for $1.24&nbsp;Billion |url=http://www.prnewswire.com/news-releases/glaxosmithkline-completes-the-purchase-of-block-drug-for-124-billion-71032672.html |url-status=usurped |archive-url=https://web.archive.org/web/20140527213852/https://www.prnewswire.com/news-releases/glaxosmithkline-completes-the-purchase-of-block-drug-for-124-billion-71032672.html |archive-date=27 May 2014 |access-date=1 August 2010 |publisher=PR Newswire}}</ref> In 2006, GSK acquired the US-based consumer healthcare company CNS Inc., whose products included Breathe Right nasal strips and FiberChoice dietary supplements, for US$566{{nbsp}}million in cash.<ref>{{cite news |last=Stouffer |first=Rick |date=9 October 2006 |title=Glaxo unit buys Breathe Right maker |work=Trib Live |url=http://triblive.com/x/pittsburghtrib/business/s_474181.html |url-status=usurped |archive-url=https://web.archive.org/web/20130728161139if_/http://triblive.com/x/pittsburghtrib/business/s_474181.html |archive-date=28 July 2013}}</ref>

[[Chris Gent]], previously CEO of [[Vodafone]], was appointed chairman of the board in 2005.<ref>{{Cite web |date=28 October 2012 |title=Sir Christopher Gent to exit GlaxoSmithKline |url=https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/9639020/Sir-Christopher-Gent-to-exit-GlaxoSmithKline.html |url-status=live |archive-url=https://web.archive.org/web/20230404113206/https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/9639020/Sir-Christopher-Gent-to-exit-GlaxoSmithKline.html |archive-date=4 April 2023 |access-date=10 September 2023 |website=The Telegraph |language=en}}</ref> GSK opened its first R&D centre in China in 2007, in Shanghai, initially focused on neurodegenerative diseases.<ref>{{cite news |url=https://www.reuters.com/article/idUSL2452000720070524 |title=Glaxo China R&D centre to target neurodegeneration |work=Reuters |date=24 May 2007 |author=Ben Hirschler |access-date=5 July 2021 |archive-date=11 August 2021 |archive-url=https://web.archive.org/web/20210811001312/https://www.reuters.com/article/idUSL2452000720070524 |url-status=live }}<br />
{{cite news |url=http://www.nature.com/news/2008/081029/full/4551168a.html |last=Cyranoski |first=David |title=Pharmaceutical futures: Made in China? |work=Nature |date=29 October 2008 |access-date=13 July 2012 |archive-date=10 June 2015 |archive-url=https://web.archive.org/web/20150610221842/http://www.nature.com/news/2008/081029/full/4551168a.html |url-status=live }}</ref> [[Andrew Witty]] became the chief executive officer in 2008.<ref>[http://www.gsk.com/about-us/corporate-executive-team.html "Corporate Executive Team"], GlaxoSmithKline. Retrieved 16 November 2013. {{webarchive |url=https://web.archive.org/web/20121014041607/http://www.gsk.com/about-us/corporate-executive-team.html |date=14 October 2012 }}</ref> Witty joined Glaxo in 1985, and had been president of GSK's Pharmaceuticals Europe since 2003.<ref>[https://www.youtube.com/watch?v=FHkj9dJ6aNE "Andrew Witty's journey from Graduate to GSK CEO"] {{Webarchive|url=https://web.archive.org/web/20170209112338/https://www.youtube.com/watch?v=FHkj9dJ6aNE |date=9 February 2017 }}, GlaxoSmithKline, 12 August 2008; [https://www.bloomberg.com/research/stocks/people/person.asp?personId=3027345&ticker=GSK "Andrew Philip Witty"], ''Bloomberg''.</ref>

In 2009, GSK acquired [[Stiefel Laboratories]], then the world's largest independent dermatology drug company, for {{US$|3.6 billion}}.<ref>{{cite news |last=Ruddick |first=Graham |url=https://www.telegraph.co.uk/finance/newsbysector/epic/gsk/5186751/GlaxoSmithKline-buys-Stiefel-for-3.6bn.html |archive-url=https://ghostarchive.org/archive/20220111/https://www.telegraph.co.uk/finance/newsbysector/epic/gsk/5186751/GlaxoSmithKline-buys-Stiefel-for-3.6bn.html |archive-date=11 January 2022 |url-access=subscription |url-status=live |title=GlaxoSmithKline buys Stiefel for $3.6bn |work=The Daily Telegraph |date=20 April 2009}}{{cbignore}}</ref> In November 2009, the FDA approved GSK's vaccine for 2009 H1N1 influenza protection, manufactured by the company's ID Biomedical Corp in Canada.<ref>{{cite web |date=16 November 2009 |title=FDA Approves Additional Vaccine for 2009 H1N1 Influenza Virus |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm190783.htm |url-status=usurped |archive-url=https://web.archive.org/web/20091119011901/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm190783.htm |archive-date=19 November 2009 |publisher=[[Food and Drug Administration (United States)|US Food and Drug Administration (FDA)]]}}</ref> Also in November 2009, GSK formed a joint venture with [[Pfizer]] to create [[ViiV Healthcare]], which specializes in HIV research.<ref>{{cite web |last=Jack |first=Andrew |url=http://www.ft.com/cms/s/0/5327ff12-2aaa-11de-8415-00144feabdc0.html |archive-url=https://ghostarchive.org/archive/20221210/http://www.ft.com/cms/s/0/5327ff12-2aaa-11de-8415-00144feabdc0.html |archive-date=10 December 2022 |url-access=subscription |title=Companies / Pharmaceuticals – GSK and Pfizer to merge HIV portfolios |work=Financial Times |date=16 April 2009}}</ref> In 2010, the company acquired Laboratorios Phoenix, an Argentine pharmaceutical company, for US$253m,<ref>{{Cite web |date=14 June 2010 |title=GSK Acquires Laboratorios Phoenix for 3m {{!}} InfoGrok |url=http://www.infogrok.com/index.php/pharma-companies/gsk-acquires-laboratorios-phoenix.html |url-status=dead |archive-url=https://web.archive.org/web/20100614180626/http://www.infogrok.com/index.php/pharma-companies/gsk-acquires-laboratorios-phoenix.html |archive-date=14 June 2010 |access-date=10 September 2023 |website=infogrok.com}}</ref> and the UK-based sports nutrition company Maxinutrition for £162{{nbsp}}million (US$256{{nbsp}}million).<ref>{{Cite news |last=Sandle |first=Paul |date=13 December 2010 |title=UPDATE 2-Glaxo buys protein-drinks firm Maxinutrition |work=Reuters |url=https://www.reuters.com/article/idUSLDE6BC0XO20101213 |url-status=live |archive-url=https://web.archive.org/web/20101216024711/https://www.reuters.com/article/idUSLDE6BC0XO20101213 |archive-date=16 December 2010}}</ref>

===2011–2022===
In 2011, in a US$660-million deal, [[Prestige Brands|Prestige Brands Holdings]] took over 17 GSK brands with sales of US$210{{nbsp}}million, including [[BC Powder]], [[Beano (dietary supplement)|Beano]], [[Ecotrin]], Fiber Choice, [[Goody's Powder]], [[Sominex]] and [[Tagamet]].<ref>{{cite news |url=http://blogs.newsobserver.com/business/gsk-sells-bc-goodys-and-other-brands |work=News & Observer |last=Ranii |first=David |title=GSK sells BC, Goody's and other brands |date=21 December 2011 |url-status=dead |archive-url=https://web.archive.org/web/20120415192244/http://blogs.newsobserver.com/business/gsk-sells-bc-goodys-and-other-brands |archive-date=15 April 2012}}</ref> In 2012, the company announced that it would invest £500{{nbsp}}million in manufacturing facilities in [[Ulverston]], northern England, designating it as the site for a previously announced biotech plant.<ref>{{Cite news |date=22 March 2012 |title=GSK confirms 500 mln stg UK investment plans |language=en |work=Reuters |url=https://www.reuters.com/article/glaxosmithkline-britain-idUSWLA506520120322 |url-status=live |access-date=10 September 2023 |archive-url=https://web.archive.org/web/20230405074247/https://www.reuters.com/article/glaxosmithkline-britain-idUSWLA506520120322 |archive-date=5 April 2023}}</ref> In May that year it acquired CellZome, a German biotech company, for US$98{{nbsp}}million,<ref>European Biotechnology News 16 May 2012. [http://www.european-biotechnology-news.com/news/news/2012-02/gsk-acquires-cellzome-100.html GSK acquires Cellzome 100%: Britain's largest drugmaker GlaxoSmithKline will pay about €75m in cash to acquire Cellzome AG completely] {{Webarchive|url=https://web.archive.org/web/20160604083405/http://www.european-biotechnology-news.com/news/news/2012-02/gsk-acquires-cellzome-100.html |date=4 June 2016 }}; John Carroll for FierceBiotech 15 May 2012 [http://www.fiercebiotech.com/story/gsk-snags-proteomics-platform-tech-98m-cellzome-buyout/2012-05-15 GSK snags proteomics platform tech in $98M Cellzome buyout]</ref> and in June, worldwide rights to [[alitretinoin]] (Toctino), an [[eczema]] drug, for US$302{{nbsp}}million.<ref>John Carroll for FiercePharma. 12 June 2012 [http://www.fiercebiotech.com/story/gsk-continues-deal-spree-302m-deal-eczema-drug/2012-06-12 GSK continues deal spree with $302M pact for Basilea eczema drug] {{Webarchive|url=https://web.archive.org/web/20140529051425/http://www.fiercebiotech.com/story/gsk-continues-deal-spree-302m-deal-eczema-drug/2012-06-12 |date=29 May 2014 }}; Basilea Pharmaceutica Press Release. 11 June 2012 [http://hugin.info/134390/R/1618919/516985.pdf Basilea enters into global agreement with Stiefel, a GSK company, for Toctino (alitretinoin)]</ref> In 2013, GSK acquired [[Human Genome Sciences]] (HGS) for US$3{{nbsp}}billion; the companies had collaborated on developing the [[lupus]] drug [[Belimumab]] (Benlysta), [[albiglutide]] for [[type 2 diabetes]], and [[darapladib]] for [[atherosclerosis]],<ref name="3Lessons">{{Cite web |last=Herper |first=Matthew |date=16 July 2012 |title=Three Lessons From GlaxoSmithKline's Purchase Of Human Genome Sciences |url=https://www.forbes.com/sites/matthewherper/2012/07/16/three-lessons-from-glaxosmithklines-purchase-of-human-genome-sciences/ |url-status=live |archive-url=https://archive.today/20140527183210/http://www.forbes.com/sites/matthewherper/2012/07/16/three-lessons-from-glaxosmithklines-purchase-of-human-genome-sciences/ |archive-date=27 May 2014 |access-date=10 September 2023 |website=Forbes |language=en}}</ref> and in September, sold its beverage division to [[Suntory]]. This included the brands [[Lucozade]] and [[Ribena]]; however, the deal did not include [[Horlicks]].<ref name="Monaghan">{{Cite news |last=Monaghan |first=Angela |date=9 September 2013 |title=Ribena and Lucozade sold to Japanese drinks giant |language=en-GB |work=The Guardian |url=https://www.theguardian.com/business/2013/sep/09/ribena-lucozade-sold-japan-glaxosmithkline |url-status=live |access-date=10 September 2023 |archive-url=https://web.archive.org/web/20230405015039/https://www.theguardian.com/business/2013/sep/09/ribena-lucozade-sold-japan-glaxosmithkline |archive-date=5 April 2023 |issn=0261-3077}}</ref>

In March 2014, GSK paid US$1{{nbsp}}billion to raise its stake in its Indian pharmaceutical unit, [[GlaxoSmithKline Pharmaceuticals]], to 75 per cent as part of a move to focus on emerging markets.<ref>{{cite news |last=Hirschler |first=Ben |date=10 March 2014 |title=GSK pays $1&nbsp;billion to lift Indian unit stake to 75 percent |work=Reuters |url=https://www.reuters.com/article/us-glaxosmithkline-india-idUSBREA2909U20140310 |url-status=live |access-date=10 March 2014 |archive-url=https://web.archive.org/web/20230405080005/https://www.reuters.com/article/us-glaxosmithkline-india-idUSBREA2909U20140310 |archive-date=5 April 2023}}</ref> In April 2014, Novartis and Glaxo agreed on more than US$20{{nbsp}}billion in deals, with Novartis selling its vaccine business to GSK and buying GSK's cancer business.<ref>{{cite news |last1=Bray |first1=Chad |last2=Jolly |first2=David |date=23 April 2014 |title=Novartis and Glaxo Agree to Trade $20 Billion in Assets |website=[[The New York Times]] |url=https://dealbook.nytimes.com/2014/04/22/novartis-announces-major-restructuring/ |url-status=live |access-date=12 March 2020 |archive-url=https://web.archive.org/web/20230405080005/https://archive.nytimes.com/dealbook.nytimes.com/2014/04/22/novartis-announces-major-restructuring/ |archive-date=5 April 2023}}</ref><ref name="wsj4222014">{{cite news |last1=Rockoff |first1=Jonathan D. |last2=Whalen |first2=Jeanne |last3=Falconi |first3=Marta |date=22 April 2014 |title=Deal Flurry Shows Drug Makers' Swing Toward Specialization |website=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/deal-flurry-shows-drug-makers-swing-toward-specialization-1398214581 |url-status=live |url-access=subscription |access-date=12 March 2020 |archive-url=https://archive.today/20230910233717/https://www.wsj.com/amp/articles/deal-flurry-shows-drug-makers-swing-toward-specialization-1398214581 |archive-date=10 September 2023}}</ref> In February 2015, GSK announced that it would acquire GlycoVaxyn, a Swiss pharmaceutical company, for US$190{{nbsp}}million,<ref>{{cite web |date=11 February 2015 |title=GEN - News Highlights:GSK Acquires GlycoVaxyn for $190M |url=http://www.genengnews.com/gen-news-highlights/gsk-acquires-glycovaxyn-for-190m/81250916/ |archive-url=https://web.archive.org/web/20230403180134/https://www.genengnews.com/ |archive-date=3 April 2023 |work=GEN}}</ref> and in June that year that it would sell two [[meningitis]] drugs to [[Pfizer]], Nimenrix and [[Mencevax]] for around US$130{{nbsp}}million.<ref>{{cite web |date=22 June 2015 |title=Pfizer Buys Two GSK Meningitis Vaccines for $130M |url=http://www.genengnews.com/gen-news-highlights/pfizer-buys-two-gsk-meningitis-vaccines-for-130m/81251415/ |archive-url=https://web.archive.org/web/20230331181324/https://www.genengnews.com/topics/drug-discovery/pfizer-buys-two-gsk-meningitis-vaccines-for-130m/ |archive-date=31 March 2023 |access-date=25 March 2016 |work=GEN}}</ref>

[[Philip Hampton]], at that time chair of the [[Royal Bank of Scotland]], became GSK chairman in September 2015.<ref>{{Cite web |last=Quinn |first=James |date=25 September 2014 |title=Sir Philip Hampton to chair Glaxo |url=https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11120385/Sir-Philip-Hampton-to-chair-Glaxo.html |url-status=live |archive-url=https://web.archive.org/web/20230404113206/https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11120385/Sir-Philip-Hampton-to-chair-Glaxo.html |archive-date=4 April 2023 |access-date=10 September 2023 |website=The Telegraph |language=en}}</ref>

On 31 March 2017, [[Emma Walmsley]] became [[Chief executive officer|CEO]]. She is the first female CEO of the company.<ref>{{Cite news |last=Herper |first=Matthew |title=GlaxoSmithKline Appoints Big Pharma's First Woman Chief Executive |work=Forbes |url=https://www.forbes.com/sites/matthewherper/2016/09/20/glaxosmithkline-appoints-big-pharmas-first-woman-chief-executive/#7f8a02ca3276 |url-status=live |access-date=11 December 2017 |archive-url=https://archive.today/20230910234224/https://www.forbes.com/sites/matthewherper/2016/09/20/glaxosmithkline-appoints-big-pharmas-first-woman-chief-executive/?sh=149dee932769 |archive-date=10 September 2023}}</ref><ref name=successionAWtoEW>{{cite news |url=https://www.telegraph.co.uk/business/2016/09/20/glaxosmithkline-names-emma-walmsley-to-replace-sir-andrew-witty/ |archive-url=https://web.archive.org/web/20160921225245/http://www.telegraph.co.uk/business/2016/09/20/glaxosmithkline-names-emma-walmsley-to-replace-sir-andrew-witty/ |archive-date=21 September 2016 |url-access=subscription |url-status=live |title=Emma Walmsley becomes latest female CEO in FTSE 100 as she replaces Sir Andrew Witty at GSK |last=Yeomans |first=Jon |newspaper=The Telegraph |publisher=Daily Telegraph, London |date=20 September 2016 |access-date=20 September 2016}}</ref>

In December 2017, Reuters reported that Glaxo had increased its stake in its Saudi Arabian unit to 75% (from 49%) taking over control from its Saudi partner Banaja KSA Holding Company.<ref>{{cite news |date=18 December 2017 |title=GlaxoSmithKline boosts stake in Saudi Arabia unit |newspaper=Reuters |url=https://www.reuters.com/article/gsk-saudi/glaxosmithkline-boosts-stake-in-saudi-arabia-unit-idUSL8N1OI1Q4 |url-status=live |archive-url=https://web.archive.org/web/20230404145936/https://www.reuters.com/article/gsk-saudi/glaxosmithkline-boosts-stake-in-saudi-arabia-unit-idUSL8N1OI1Q4 |archive-date=4 April 2023}}</ref>

With respect to [[rare disease]]s, the company divested its portfolio of [[gene therapy]] drugs to Orchard Therapeutics in April 2018.<ref name=":0" /> In November 2018, [[Reuters]] reported that [[Unilever]] was in prime position to acquire GSK's interest in its Indian unit, GlaxoSmithKline Consumer Healthcare Ltd, in a sale that could generate around US$4{{nbsp}}billion for the company.<ref name="pole">{{cite news |last1=Gruber |first1=Kane Wu |date=28 November 2018 |title=Unilever in pole position to swallow GSK's Indian Horlicks business |newspaper=Reuters |url=https://uk.reuters.com/article/uk-gsk-m-a-india/nestl-unilever-in-pole-position-for-gsks-indian-horlicks-business-reports-idUKKCN1NX0F0 |url-status=dead |access-date=28 November 2018 |archive-url=https://web.archive.org/web/20181128071040/https://uk.reuters.com/article/uk-gsk-m-a-india/nestl-unilever-in-pole-position-for-gsks-indian-horlicks-business-reports-idUKKCN1NX0F0 |archive-date=28 November 2018}}</ref> [[Nestlé]] and [[Coca-Cola]] have also been reported to be interested in the business unit as they look to strengthen their presence in India.<ref name=pole/><ref>{{cite web |last=Sagonowsky |first=Eric |date=28 November 2018 |title=GlaxoSmithKline taps Unilever as lead bidder in Indian Horlicks buyout: report |url=https://www.fiercepharma.com/pharma/unilever-gsk-late-stage-talks-for-horlicks-buyout-india-reuters |url-status=live |archive-url=https://web.archive.org/web/20230405015037/https://www.fiercepharma.com/pharma/unilever-gsk-late-stage-talks-for-horlicks-buyout-india-reuters |archive-date=5 April 2023 |access-date=28 November 2018 |publisher=FiercePharma}}</ref> On 3 December 2018, GSK announced that Unilever would acquire the Indian-listed GlaxoSmithKline Consumer Healthcare business for US$3.8{{nbsp}}billion (£2.98{{nbsp}}billion). Unilever will pay the majority of the deal in cash, with the remaining being paid in shares in its Indian operation, [[Hindustan Unilever|Hindustan Unilever Limited]]. Upon completion, GSK will then own around 5.7% of Hindustan Unilever Limited, selling those shares in a number of tranches.<ref>{{cite news |date=3 December 2018 |title=Unilever swallows GSK's Indian Horlicks business for $3.8&nbsp;billion |work=Reuters |url=https://uk.reuters.com/article/uk-gsk-m-a-unilever/unilever-swallows-gsks-indian-horlicks-business-for-3-8-billion-idUKKBN1O20P3 |url-status=dead |access-date=3 December 2018 |archive-url=https://web.archive.org/web/20181203114000/https://uk.reuters.com/article/us-gsk-m-a-unilever/unilever-swallows-gsks-indian-horlicks-business-for-3-8-billion-idUKKBN1O20S7 |archive-date=3 December 2018}}</ref> The same day, the company also announced it would acquire oncology specialist, [[Tesaro]], for US$5.1{{nbsp}}billion. The deal will give GSK control of ovarian cancer treatment, [[Zejula]] - a member of the class of [[poly ADP ribose polymerase]] (PARP) inhibitors.<ref>{{cite news |last=Hirschler |first=Ben |date=3 December 2018 |title=GSK slides after buying cancer firm Tesaro for hefty $5.1&nbsp;billion |work=Reuters |url=https://uk.reuters.com/article/us-tesaro-m-a-gsk/gsk-slides-after-buying-cancer-firm-tesaro-for-hefty-5-1-billion-idUKKBN1O218H |url-status=dead |access-date=3 December 2018 |archive-url=https://web.archive.org/web/20181203161201/https://uk.reuters.com/article/uk-tesaro-m-a-gsk/gsk-slides-after-buying-cancer-firm-tesaro-for-hefty-5-1-billion-idUKKBN1O218B |archive-date=3 December 2018}}</ref>

In October 2019, GSK agreed to sell its [[rabies]] vaccine, [[RabAvert]], and its [[tick-borne encephalitis]] vaccine, [[Encepur]], to [[Bavarian Nordic]] for US$1.06{{nbsp}}billion (€955{{nbsp}}million).<ref>{{Cite web |url=https://www.fiercepharma.com/vaccines/gsk-sells-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic-for-up-to-1-06b |title=Zeroing in on fast-growing vaccines, GSK sheds 2 shots to Bavarian Nordic for up to $1.1B |last=Sagonowsky |first=Eric |date=21 October 2019 |website=FiercePharma |url-status=live |archive-url=https://web.archive.org/web/20200105160030/https://www.fiercepharma.com/vaccines/gsk-sells-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic-for-up-to-1-06b |archive-date=5 January 2020 |access-date=26 January 2020}}</ref><ref>{{Cite web |date=21 October 2019 |title=GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic |url=https://www.gsk.com/en-gb/media/press-releases/gsk-agrees-to-divest-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic/ |url-status=live |archive-url=https://web.archive.org/web/20230804142613/https://www.gsk.com/en-gb/media/press-releases/gsk-agrees-to-divest-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic/ |archive-date=4 August 2023 |access-date=26 January 2020 |website=GSK }}</ref>

In July 2020, GSK acquired a 10% stake in German biotech company [[CureVac]].<ref>{{Cite news |last1=Schuetze |first1=Arno |last2=Aripaka |first2=Pushkala |date=20 July 2020 |title=GSK buys 10% of CureVac in vaccine tech deal |newspaper=Reuters |url=https://uk.reuters.com/article/us-gsk-curevac-stake-idUKKCN24L0JR |url-status=dead |archive-url=https://web.archive.org/web/20200720223837/https://uk.reuters.com/article/us-gsk-curevac-stake-idUKKCN24L0JR |archive-date=20 July 2020 |via=uk.reuters.com}}</ref>

==== GSK–Novartis consumer healthcare buy-out ====
In March 2018, GSK announced that it has reached an agreement with [[Novartis]] to acquire Novartis's 36.5% stake in their Consumer Healthcare Joint Venture for US$13{{nbsp}}billion (£9.2{{nbsp}}billion).<ref>{{cite news |last=Shields |first=Michael |date=27 March 2018 |title=GSK buys out Novartis in $13&nbsp;billion consumer healthcare shake-up |work=Reuters |url=https://uk.reuters.com/article/us-novartis-gsk/gsk-buys-out-novartis-in-13-billion-consumer-healthcare-shake-up-idUKKBN1H30FK |url-status=deviated |access-date=27 March 2018 |archive-url=https://web.archive.org/web/20180327111340/https://uk.reuters.com/article/us-novartis-gsk/gsk-buys-out-novartis-in-13-billion-consumer-healthcare-shake-up-idUKKBN1H30FK |archive-date=27 March 2018}}</ref><ref name=":0">{{Cite news |last=<!--no byline--> |date=21 July 2018 |title=GlaxoSmithKline considers splitting up the group - FT |work=Reuters |url=https://in.reuters.com/article/gsk-divestiture/glaxosmithkline-considers-splitting-up-the-group-ft-idINKBN1KB07N |url-status=dead |access-date=23 July 2018 |archive-url=https://web.archive.org/web/20180721085717/https://in.reuters.com/article/gsk-divestiture/glaxosmithkline-considers-splitting-up-the-group-ft-idINKBN1KB07N |archive-date=21 July 2018}}</ref>

==== GSK–Pfizer joint venture ====
In December 2018, GSK announced that it, along with [[Pfizer]], had reached an agreement to merge and combine their consumer healthcare divisions into a single entity. The combined entity would have sales of around £9.8{{nbsp}}billion ($12.7{{nbsp}}billion), with GSK maintaining a 68% controlling stake in the joint venture. Pfizer would own the remaining 32% shareholding. The deal builds on an earlier 2018 deal where GSK bought out Novartis' stake in the GSK-Novartis consumer healthcare joint business.<ref name="split">{{cite news |last=Hirschler |first=Ben |date=19 December 2018 |title=Drugmaker GSK to split after striking Pfizer consumer health deal |work=Reuters |url=https://uk.reuters.com/article/us-pfizer-m-a-gsk/drugmaker-gsk-to-split-after-striking-pfizer-consumer-health-deal-idUKKBN1OI0IP |url-status=deviated |access-date=19 December 2018 |archive-url=https://web.archive.org/web/20181219125857/https://uk.reuters.com/article/uk-pfizer-m-a-gsk/drugmaker-gsk-to-split-after-striking-pfizer-consumer-health-deal-idUKKBN1OI0IN |archive-date=19 December 2018}}</ref>

==== Subsequent split ====
[[File:GSK logo 2014.svg|thumb|100px|Prior logo before 9 June 2022]]
The culmination of the Consumer Healthcare string of deals will result in GSK splitting into two separate companies, via a demerger and subsequent listing of the joint venture. This will create two publicly traded companies, one focusing on pharmaceuticals and research & development, the other on consumer healthcare. On 22 February 2022, GSK announced that the spin-off consumer healthcare company will be called [[Haleon]].<ref name=split/><ref>{{cite news |last=Freeman |first=Simon |date=22 February 2022 |title=Hello, Haleon: GlaxoSmithKline reveals name of £60bn consumer health spin-out |newspaper=Evening Standard |url=https://www.standard.co.uk/business/glaxosmithkline-gsk-names-spinoff-haleon-sensodyne-walmsley-elliott-b983928.html |url-status=live |access-date=23 February 2022 |archive-url=https://web.archive.org/web/20230405015033/https://www.standard.co.uk/business/glaxosmithkline-gsk-names-spinoff-haleon-sensodyne-walmsley-elliott-b983928.html |archive-date=5 April 2023}}</ref>

In January 2022, the company announced that they had received three unsolicited offers from [[Unilever]] to acquire the Consumer Healthcare business unit, with the final proposal valuing the business unit at £50 billion (£41.7 billion in cash, plus £8.3 billion in Unilever shares).<ref>{{Cite news |last1=Cavale |first1=Siddharth |last2=Burger |first2=Ludwig |last3=Dey |first3=Mrinmay |date=15 January 2022 |title=GSK rejects 50-billion-pound Unilever offer for consumer assets |newspaper=Reuters |url=https://www.reuters.com/business/retail-consumer/unilever-offers-50-bln-pounds-gsk-unit-report-2022-01-15/ |archive-url=https://web.archive.org/web/20220115110019/https://www.reuters.com/business/retail-consumer/unilever-offers-50-bln-pounds-gsk-unit-report-2022-01-15/ |archive-date=15 January 2022 |via=www.reuters.com}}</ref>

Subsequently, GSK declined all outside offers/attempts to acquire its consumer healthcare business and moved forward with its plan to complete the demerger from the main biopharmaceutical business.<ref>{{Cite web |url=https://www.ft.com/content/85f28cd9-ca18-4f2b-8346-c22efdfe1382 |archive-url=https://ghostarchive.org/archive/20221210/https://www.ft.com/content/85f28cd9-ca18-4f2b-8346-c22efdfe1382 |archive-date=10 December 2022 |url-access=subscription |title=Pfizer to exit GSK consumer health joint venture after London listing |newspaper=Financial Times |date=1 June 2022 |access-date=15 June 2022}}</ref>

=== Recent developments ===
In April 2022, the business announced it would acquire Sierra Oncology Inc for $1.9 billion ($55 per share).<ref>{{Cite news |last1=Grover |first1=Natalie |last2=Shabong |first2=Yadarisa |date=13 April 2022 |title=GSK to buy Sierra Oncology amid pressure to boost drug pipeline |newspaper=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-buy-sierra-oncology-19-billion-2022-04-13/ |archive-url=https://web.archive.org/web/20220413065844/https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-buy-sierra-oncology-19-billion-2022-04-13/ |archive-date=13 April 2022 |via=www.reuters.com}}</ref> In May 2022, GSK announced it would acquire Affinivax and its phase II 24-valent [[pneumococcal]] vaccine candidate for up to $3.3 billion, strengthening its vaccine business.<ref>{{cite news |last=Keown |first=Alex |date=31 May 2022 |title=GSK Bolsters Vaccines Business with $3.3B Affinivax Buy |newspaper=Biospace |url=https://www.biospace.com/article/gsk-bolsters-vaccines-business-with-affinivax-buy/?s=79 |access-date=9 June 2022 |archive-url=https://web.archive.org/web/20230205012142/https://www.biospace.com/article/gsk-bolsters-vaccines-business-with-affinivax-buy/?s=79 |archive-date=5 February 2023}}</ref>

On 16 May 2022, the company changed its name from GlaxoSmithKline to GSK.<ref>{{cite web |date=16 May 2022 |title=Change of name |url=https://www.londonstockexchange.com/news-article/GSK/change-of-name-to-gsk-plc/15454280 |url-status=live |archive-url=https://web.archive.org/web/20220517145739/https://www.londonstockexchange.com/news-article/GSK/change-of-name-to-gsk-plc/15454280 |archive-date=17 May 2022 |access-date=2 June 2022 |publisher=London Stock Exchange}}</ref>

In April 2023, GSK announced it would acquire Bellus Health Inc. for $2 billion.<ref>{{Cite web |last=Susin |first=Michael |date=18 April 2023 |title=GSK: To Acquire The Late-stage Biopharmaceutical Group For $14.75 Per Share |url=https://www.marketwatch.com/story/gsk-to-acquire-the-late-stage-biopharmaceutical-group-for-14-75-per-share-ed67d6d |url-status=usurped |archive-url=https://web.archive.org/web/20230418064221/https://www.marketwatch.com/story/gsk-to-acquire-the-late-stage-biopharmaceutical-group-for-14-75-per-share-ed67d6d |archive-date=18 April 2023 |access-date=18 April 2023 |website=MarketWatch |language=EN-US}}</ref>

In February 2024, the company acquired [[Aiolos Bio]] for over $1 billion, adding to its existing asthma business through [[AIO-001]] a long-acting [[monoclonal antibody]] that targets the [[thymic stromal lymphopoietin]] cytokine.<ref>{{cite web |url=https://www.biospace.com/article/gsk-puts-1-4b-on-the-line-in-aiolos-acquisition-to-boost-asthma-pipeline/?s=79 |title=GSK Puts $1.4B on the Line in Aiolos Acquisition to Boost Asthma Pipeline|date=9 January 2024 }}</ref><ref>{{Cite web |date=February 16, 2024 |title=GSK completes acquisition of Aiolos Bio for up to $1.4 bln |url=https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-completes-acquisition-aiolos-bio-up-14-bln-2024-02-15/ |access-date=February 16, 2024 |website=Reuters}}</ref>

In May 2024, GSK sold off its 4.2% shares in Haleon for $1.58 billion.<ref>{{Cite web |title=GSK sells off remaining stake in Haleon |url=https://www.ft.com/content/557b7f43-da17-46b6-aa1c-740c1859fa96 |access-date=2024-05-17 |website=www.ft.com|date=17 May 2024 | vauthors = Johnston I }}</ref><ref>{{Cite web |title=GSK to sell remaining 4.2% stake in Haleon |url=https://www.sharecast.com/news/news-and-announcements/gsk-to-sell-remaining-42-stake-in-haleon--16794044.html |access-date=2024-05-17 |website=Sharecast |language=en}}</ref><ref>{{Cite news |title=GSK Sells Last Haleon Shares for $1.58 Bln |newspaper=Marketwatch |url=https://www.marketwatch.com/story/gsk-sells-last-haleon-shares-for-1-58-bln-c99ca63f}}</ref>

In July 2024, GSK moved its headquarters from Brentford to [[Oxford Street|New Oxford Street]] in central London.<ref>{{Cite web |date=2024-07-13 |title=GSK moves to new HQ in return to central London |url=https://www.independent.co.uk/news/uk/gsk-london-emma-walmsley-brentford-city-b2579395.html |access-date=2024-07-16 |website=The Independent |language=en}}</ref>

====Acquisition-history diagram====
{{hidden begin|border=1px #aaa solid|title=GlaxoSmithKline Structure|ta1=center}}
{{Tree list}}
* '''GSK'''
** GlaxoSmithKline
*** SmithKline Beecham Plc {{small|(Renamed 1989)}}
**** SmithKline Beckman {{small|(Renamed 1982)}}
***** SmithKline-RIT {{small|(Renamed 1968)}}
****** [[Smith, Kline & French]] {{small|(Reorganized 1929 into Smith Kline and French Laboratories)}}
******* French, Richards and Company {{small|(Acquired 1891)}}
******* Smith, Kline and Company
****** [[Recherche et Industrie Thérapeutiques]] {{small|(Acquired 1968)}}
***** [[Beckman Instruments, Inc.]] {{small|(Merged 1982, Sold 1989)}}
****** Specialized Instruments Corp. {{small|(Acquired 1954)}}
****** Offner Electronics {{small|(Acquired 1961)}}
***** International Clinical Laboratories {{small|(Acquired 1989)}}
***** Reckitt & Colman {{small|(Acquired 1999)}}
**** [[Beecham Group]] Plc {{small|(Merged 1989)}}
***** Beecham Group Ltd
****** [[S. E. Massengill Company]] {{small|(Acquired 1971)}}
****** C.L. Bencard {{small|(Acquired 1953)}}
****** County Chemicals
***** Norcliff Thayer {{small|(Acquired 1986)}}
*** Glaxo Wellcome
**** Glaxo {{small|(Merged 1995)}}
***** Joseph Nathan & Co
***** [[Allen & Hanburys]] {{small|(Founded 1715, acquired 1958)}}
***** Meyer Laboratories {{small|(Merged 1978)}}
***** Affymax {{small|(Acquired 1995)}}
**** Wellcome Foundation {{small|(Renamed 1924, merged 1995)}}
***** Burroughs Wellcome & Company {{small|(Founded 1880)}}
***** McDougall & Robertson Inc {{small|(Acquired 1959)}}
** [[Block Drug]] {{small|(Acquired 2001)}}
** CNS Inc. {{small|(Acquired 2006)}}
** [[Stiefel Laboratories]] {{small|(Acquired 2009)}}
** Laboratorios Phoenix {{small|(Acquired 2010)}}
** Maxinutrition {{small|(Acquired 2010)}}
** CellZome {{small|(Acquired 2011)}}
** [[Human Genome Sciences]] {{small|(Acquired 2013)}}
** GlycoVaxyn {{small|(Acquired 2015)}}
** [[Tesaro]] {{small|(Acquired 2019)}}
** Sitari Pharmaceuticals {{small|(Acquired 2019)}}
** Sierra Oncology {{small|(Acquired 2022)}}
** Affinivax {{small|(Acquired 2022)}}
** Bellus Health Inc. {{small|(Acquired 2023)}}
** Aiolos Bio {{small|(Acquired 2024)}}
{{Tree list/end}}
{{Hidden end}}